NSG BioLabs, the largest provider of biotech co-working laboratory and office space in Singapore, has entered into a new partnership with Eppendorf, a prominent international life science company specializing in the development, manufacturing, and distribution of laboratory instruments, consumables, and services worldwide. This collaboration aims to bolster biotech startups by offering essential resources such as product and application expertise, as well as leveraging extensive networks to advance research and development efforts.
Eppendorf and NSG BioLabs have formed a strategic partnership aimed at cultivating an environment conducive to the success of NSG BioLabs’ resident companies. Through this collaboration, residents gain privileged access to Eppendorf’s state-of-the-art equipment, consumables, and services. These resources enable accelerated research progress and facilitate the expansion of their innovative endeavors. Together, Eppendorf and NSG BioLabs are actively shaping the future of life sciences by fostering significant discoveries.
Since 2019, NSG BioLabs has been supporting innovators in developing transformative solutions across health, biomedical, agrifood, and industrial biotechnology sectors. Their focus areas include precision medicine, nucleic acids, AI-driven drug discovery, synthetic biology, and other impactful fields. With the largest co-working biotech laboratory and office space in Singapore, along with extensive networks encompassing local and international partners, suppliers, and industry experts, NSG BioLabs has facilitated the growth of over 40 resident companies. Among these residents are several multinational corporations worth billions and numerous promising startups that have achieved significant milestones. Collectively, startup residents have secured nearly US$400 million in funding and generated employment opportunities for hundreds of individuals.
“We are thrilled to announce our strategic partnership with Eppendorf, a leader in life sciences equipment and services. At NSG BioLabs, fostering an environment where our residents can thrive is our top priority. This collaboration will provide our residents with exclusive access to Eppendorf’s cutting-edge equipment, consumables, and services, empowering them to accelerate their research and scale their innovations. Together, we are shaping the future of life sciences and driving impactful discoveries”, said Daphne Teo, CEO and Founder of NSG BioLabs.
“Empowering innovative biotech startups is of strategic importance to the Eppendorf Group, as they drive the future of medical innovation and the development of new treatments. Eppendorf’s purpose is to help improve human living conditions and we have been clearly committed for almost 80 years in supporting scientists around the world. Eppendorf is proud to engage in a partnership with NSG Biolabs, affirming its shared vision for supporting innovators in creating impactful biotech solutions. Being part of this scientific community is crucial and this collaboration will be the catalyst for transformative breakthroughs in Singapore and beyond”, said Surendran Krishnamurthi, Managing Director Eppendorf Southeast Asia.
Since its inception, NSG BioLabs has supported biotech startups and multinational companies with BSL-2-certified private and shared laboratory spaces, offices, equipment, and privileged access to service providers and suppliers. It has become a key hub for biotech innovation, recognized as one of the largest private biotech incubators in the region. Supported by partnerships and strategic investments from entities like Celadon Partners and ClavystBio, NSG BioLabs continues to enhance its infrastructure, services, and networks to benefit its growing community.